ZYBERNO
Stock Report
Updated Aug 31, 2026

LeonaBio, Inc. (LONA)

Healthcare • NASDAQ

$7.92

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
LeonaBio, Inc. (LONA) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-411.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.03x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-3,274.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LeonaBio, Inc. (LONA) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, LONA generated -$97.20M in Owner Earnings. Capital was deployed as follows: $33.00K invested in capital expenditures. Reinvestment rate: 1.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:7.92
Market Cap:$187.91M

Valuation Multiples (2)

P/B Ratio:5.59x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$157.11M

Price Action & Momentum (3)

Momentum Percentile:97 / 100
% of 52-Week High:55.7%
B. Profitability Assessment

Return Metrics (5)

ROA:-225.7%
Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-33.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$340.79
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:51.9%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.01x
Quick Ratio:7.01x
Cash Ratio:4.13x

Leverage Analysis (3)

Debt To Equity Ttm:0.03x
Debt-to-Equity Ratio:0.03x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:46,991,000.00
Cash And Cash Equivalents:32,323,000.00
Long Term Debt:$1.03M
Net Debt:-$30.80M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$122.11M

Bottom Line Performance (3)

-$141.46M
Income Before Tax:-$105.61M
Ebitda Ttm:-121,146,000.00

Operating Expenses (5)

Operating Expenses:122,106,000.00
R And D Expense:33,501,000.00
Sga Expense:21,271,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$56.89M
Current Assets:$54.81M
Ppe Net:5,739,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:23,299,000.00
Current Liabilities:7,817,000.00
Long Term Debt:$1.03M
Short Term Debt:$491.00K

Equity & Capital (3)

Equity:$33.60M
Retained Earnings:-$563.71M
Common Stock:400,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:2,420,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,181,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$51.97M-$52.00M

Investment Activities (2)

Investing Cash Flow:-$15.54M
Capital Expenditures Ttm:33,000.00

Financing Activities (3)

Financing Cash Flow:$34.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:89,991,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:960,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-26.82
-$26.82
Earnings Per Share Ttm:-$5.96

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.93

Book Value & Capital (2)

Book Value Per Share:$1.42
Cash Per Share:1.36

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$97.20M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-33.6%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-46.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:LONA
Company Name:LeonaBio, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:23.73M
Shares Outstanding Basic:23.73M
Shares Outstanding Diluted:23.73M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 21:26:13 UTC
Data Timestamp:2026-08-19T23:30:07.770136
Scroll to Top